| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 17 | 2021 | 132 | 5.300 |
Why?
|
| Deep Brain Stimulation | 10 | 2020 | 54 | 4.810 |
Why?
|
| Supranuclear Palsy, Progressive | 10 | 2022 | 20 | 3.610 |
Why?
|
| Subthalamic Nucleus | 6 | 2018 | 22 | 2.820 |
Why?
|
| Parkinsonian Disorders | 5 | 2019 | 21 | 1.540 |
Why?
|
| Gait | 3 | 2015 | 80 | 1.420 |
Why?
|
| Deglutition Disorders | 2 | 2022 | 115 | 1.370 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2019 | 16 | 1.250 |
Why?
|
| Deglutition | 2 | 2015 | 73 | 1.010 |
Why?
|
| Movement Disorders | 1 | 2022 | 44 | 0.880 |
Why?
|
| Essential Tremor | 1 | 2020 | 6 | 0.770 |
Why?
|
| Implantable Neurostimulators | 1 | 2020 | 12 | 0.770 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 45 | 0.750 |
Why?
|
| Brain | 9 | 2019 | 2216 | 0.720 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 115 | 0.710 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2020 | 201 | 0.700 |
Why?
|
| Health Status Disparities | 1 | 2021 | 170 | 0.680 |
Why?
|
| Defibrillators, Implantable | 1 | 2020 | 129 | 0.680 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2016 | 35 | 0.670 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 240 | 0.630 |
Why?
|
| Disease Progression | 5 | 2022 | 1531 | 0.630 |
Why?
|
| Antiparkinson Agents | 3 | 2013 | 15 | 0.620 |
Why?
|
| Tremor | 2 | 2019 | 22 | 0.600 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 371 | 0.570 |
Why?
|
| Ataxia | 2 | 2014 | 37 | 0.540 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2015 | 19 | 0.530 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2016 | 73 | 0.530 |
Why?
|
| tau Proteins | 3 | 2019 | 62 | 0.520 |
Why?
|
| Male | 29 | 2021 | 40965 | 0.510 |
Why?
|
| Aged | 20 | 2021 | 18415 | 0.510 |
Why?
|
| Catechol O-Methyltransferase | 6 | 2003 | 68 | 0.490 |
Why?
|
| Humans | 47 | 2022 | 86643 | 0.490 |
Why?
|
| Chorea | 1 | 2014 | 13 | 0.480 |
Why?
|
| Methamphetamine | 4 | 2004 | 82 | 0.470 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2014 | 104 | 0.450 |
Why?
|
| Nortropanes | 1 | 2012 | 10 | 0.440 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1801 | 0.440 |
Why?
|
| Dopamine Agonists | 1 | 2012 | 27 | 0.430 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 92 | 0.430 |
Why?
|
| Fragile X Syndrome | 1 | 2012 | 15 | 0.420 |
Why?
|
| Iodine Radioisotopes | 1 | 2012 | 134 | 0.420 |
Why?
|
| Nerve Tissue Proteins | 4 | 2022 | 503 | 0.400 |
Why?
|
| Multiple System Atrophy | 2 | 2022 | 4 | 0.400 |
Why?
|
| Melatonin | 2 | 2021 | 47 | 0.380 |
Why?
|
| Biomarkers | 5 | 2019 | 1718 | 0.380 |
Why?
|
| Neurons | 4 | 2004 | 1546 | 0.380 |
Why?
|
| Middle Aged | 17 | 2021 | 25028 | 0.380 |
Why?
|
| Disease Management | 1 | 2012 | 327 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 238 | 0.360 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 6 | 0.360 |
Why?
|
| Treatment Outcome | 8 | 2019 | 7993 | 0.350 |
Why?
|
| Female | 24 | 2021 | 44532 | 0.350 |
Why?
|
| Double-Blind Method | 5 | 2019 | 1823 | 0.340 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 428 | 0.340 |
Why?
|
| Basal Ganglia Diseases | 1 | 2018 | 9 | 0.340 |
Why?
|
| Dopamine | 4 | 2004 | 275 | 0.330 |
Why?
|
| Neurofilament Proteins | 1 | 2017 | 13 | 0.320 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 44 | 0.320 |
Why?
|
| Global Health | 1 | 2019 | 193 | 0.310 |
Why?
|
| Machine Learning | 2 | 2019 | 232 | 0.300 |
Why?
|
| Oligopeptides | 2 | 2017 | 179 | 0.300 |
Why?
|
| Dystonia | 1 | 2017 | 29 | 0.300 |
Why?
|
| Basal Ganglia | 1 | 2016 | 42 | 0.290 |
Why?
|
| Drug Utilization | 1 | 2017 | 65 | 0.280 |
Why?
|
| Germany | 3 | 2020 | 72 | 0.280 |
Why?
|
| Wallerian Degeneration | 1 | 2006 | 2 | 0.280 |
Why?
|
| Neurotoxins | 1 | 2006 | 49 | 0.280 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2006 | 45 | 0.270 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 1204 | 0.250 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2004 | 5 | 0.250 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2006 | 68 | 0.250 |
Why?
|
| Metallothionein | 1 | 2004 | 13 | 0.250 |
Why?
|
| Serotonin | 1 | 2006 | 218 | 0.250 |
Why?
|
| Quality of Life | 1 | 2012 | 1585 | 0.240 |
Why?
|
| Cocaine | 1 | 2004 | 76 | 0.240 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6509 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 1621 | 0.230 |
Why?
|
| Striatonigral Degeneration | 1 | 2022 | 1 | 0.220 |
Why?
|
| Olivopontocerebellar Atrophies | 1 | 2022 | 6 | 0.220 |
Why?
|
| Membrane Transport Proteins | 2 | 2002 | 166 | 0.220 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 584 | 0.210 |
Why?
|
| Comorbidity | 2 | 2021 | 943 | 0.210 |
Why?
|
| Corpus Striatum | 2 | 2016 | 86 | 0.200 |
Why?
|
| Spain | 1 | 2020 | 33 | 0.200 |
Why?
|
| France | 1 | 2020 | 47 | 0.200 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 34 | 0.190 |
Why?
|
| Italy | 1 | 2020 | 106 | 0.190 |
Why?
|
| Blotting, Northern | 5 | 2004 | 256 | 0.190 |
Why?
|
| Electric Countershock | 1 | 2020 | 47 | 0.190 |
Why?
|
| Body Temperature | 1 | 2000 | 124 | 0.190 |
Why?
|
| Disulfiram | 1 | 2020 | 8 | 0.190 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 294 | 0.180 |
Why?
|
| Copper | 1 | 2020 | 71 | 0.180 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2020 | 47 | 0.180 |
Why?
|
| Neurites | 1 | 2019 | 35 | 0.180 |
Why?
|
| Arginine | 1 | 2020 | 136 | 0.180 |
Why?
|
| Tauopathies | 1 | 2019 | 9 | 0.180 |
Why?
|
| Interferons | 1 | 2020 | 133 | 0.180 |
Why?
|
| Dopamine Agents | 1 | 2019 | 29 | 0.170 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 91 | 0.170 |
Why?
|
| Down-Regulation | 4 | 2006 | 504 | 0.170 |
Why?
|
| United States | 5 | 2021 | 6672 | 0.170 |
Why?
|
| RNA Splicing | 1 | 2020 | 142 | 0.170 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 1998 | 8 | 0.170 |
Why?
|
| Alternative Splicing | 1 | 2020 | 201 | 0.160 |
Why?
|
| Models, Animal | 1 | 2019 | 263 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2020 | 157 | 0.160 |
Why?
|
| Estrogens | 1 | 1999 | 200 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2004 | 44 | 0.160 |
Why?
|
| Consensus | 1 | 2019 | 335 | 0.160 |
Why?
|
| Formamides | 1 | 1997 | 2 | 0.160 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 29 | 0.160 |
Why?
|
| Ethidium | 1 | 1997 | 13 | 0.160 |
Why?
|
| Time Factors | 3 | 2018 | 5210 | 0.160 |
Why?
|
| Cerebellum | 1 | 2019 | 247 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 1998 | 106 | 0.160 |
Why?
|
| Cisplatin | 1 | 2020 | 612 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2005 | 689 | 0.150 |
Why?
|
| Valine | 1 | 1997 | 69 | 0.150 |
Why?
|
| Methionine | 1 | 1997 | 66 | 0.150 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 399 | 0.150 |
Why?
|
| Torticollis | 1 | 2016 | 11 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2000 | 673 | 0.150 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 329 | 0.150 |
Why?
|
| Saliva | 1 | 2017 | 122 | 0.150 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 31 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2021 | 534 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 592 | 0.140 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 242 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2002 | 1920 | 0.140 |
Why?
|
| Neoplasms | 2 | 2021 | 2898 | 0.130 |
Why?
|
| Transcription, Genetic | 2 | 2001 | 1135 | 0.130 |
Why?
|
| Levodopa | 1 | 2015 | 36 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 639 | 0.130 |
Why?
|
| Calcium Channels | 1 | 2016 | 182 | 0.130 |
Why?
|
| Animals | 12 | 2020 | 26582 | 0.130 |
Why?
|
| Barium Sulfate | 1 | 2014 | 43 | 0.130 |
Why?
|
| Paraneoplastic Cerebellar Degeneration | 1 | 2014 | 1 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2019 | 2767 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 930 | 0.120 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 3 | 2002 | 12 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 819 | 0.110 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 26 | 0.110 |
Why?
|
| Myoclonus | 1 | 2013 | 15 | 0.110 |
Why?
|
| Hypokinesia | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mice | 7 | 2020 | 11352 | 0.110 |
Why?
|
| Amyloid beta-Peptides | 2 | 2017 | 203 | 0.110 |
Why?
|
| Electron Transport Complex IV | 2 | 2002 | 47 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2014 | 268 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1805 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2017 | 460 | 0.100 |
Why?
|
| Atrophy | 2 | 2016 | 117 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2012 | 171 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1019 | 0.100 |
Why?
|
| alpha-Synuclein | 2 | 2022 | 13 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 1219 | 0.090 |
Why?
|
| Prognosis | 2 | 2018 | 3679 | 0.090 |
Why?
|
| Austria | 2 | 2019 | 19 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2438 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2004 | 1981 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2018 | 4213 | 0.090 |
Why?
|
| Rats | 3 | 2006 | 3990 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2360 | 0.080 |
Why?
|
| Central Nervous System Agents | 1 | 2017 | 15 | 0.080 |
Why?
|
| Syndrome | 1 | 2018 | 446 | 0.080 |
Why?
|
| Central Nervous System | 1 | 1998 | 151 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 3362 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2021 | 8489 | 0.080 |
Why?
|
| Australia | 1 | 2017 | 99 | 0.070 |
Why?
|
| Canada | 1 | 2017 | 204 | 0.070 |
Why?
|
| p-Chloroamphetamine | 1 | 2006 | 1 | 0.070 |
Why?
|
| 5,7-Dihydroxytryptamine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 2426 | 0.070 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2006 | 10 | 0.070 |
Why?
|
| Fenfluramine | 1 | 2006 | 20 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2903 | 0.070 |
Why?
|
| Serotonin Agents | 1 | 2006 | 12 | 0.070 |
Why?
|
| Europe | 1 | 2017 | 309 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 307 | 0.070 |
Why?
|
| Retinitis Pigmentosa | 1 | 2005 | 35 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2001 | 3030 | 0.070 |
Why?
|
| Models, Neurological | 1 | 2018 | 405 | 0.070 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 113 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2017 | 1106 | 0.060 |
Why?
|
| Axons | 1 | 2006 | 174 | 0.060 |
Why?
|
| Amphetamine | 1 | 2005 | 101 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 176 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2705 | 0.060 |
Why?
|
| Base Sequence | 2 | 1999 | 2330 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1578 | 0.060 |
Why?
|
| Mesencephalon | 2 | 2001 | 64 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2004 | 94 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 183 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2017 | 371 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2003 | 937 | 0.060 |
Why?
|
| Estradiol | 1 | 2003 | 252 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2016 | 814 | 0.050 |
Why?
|
| Autopsy | 1 | 2022 | 116 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2003 | 498 | 0.050 |
Why?
|
| Membrane Transport Modulators | 1 | 2002 | 2 | 0.050 |
Why?
|
| Synaptosomes | 1 | 2002 | 9 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2003 | 268 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 15 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 36 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2601 | 0.050 |
Why?
|
| Adult | 3 | 2019 | 25648 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 5976 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2002 | 122 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 172 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1753 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2002 | 290 | 0.050 |
Why?
|
| Gene Library | 1 | 2001 | 130 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 307 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 2002 | 74 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 582 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 176 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2001 | 7 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 267 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 623 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 927 | 0.050 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 2000 | 12 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2001 | 74 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2022 | 487 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2271 | 0.050 |
Why?
|
| Transcytosis | 1 | 2020 | 3 | 0.050 |
Why?
|
| Nanomedicine | 1 | 2020 | 14 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 50 | 0.050 |
Why?
|
| Oxides | 1 | 2020 | 43 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 1384 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1961 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2019 | 4 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1924 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1999 | 34 | 0.040 |
Why?
|
| Anisotropy | 1 | 2019 | 62 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 303 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3640 | 0.040 |
Why?
|
| COS Cells | 1 | 1999 | 166 | 0.040 |
Why?
|
| Temperature | 1 | 2000 | 396 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 696 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 303 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 1999 | 268 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 178 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 458 | 0.040 |
Why?
|
| beta Catenin | 1 | 2020 | 251 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 646 | 0.040 |
Why?
|
| Postural Balance | 1 | 2017 | 42 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 23 | 0.040 |
Why?
|
| Protein Denaturation | 1 | 1997 | 106 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 969 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 1997 | 165 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2000 | 374 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 212 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 418 | 0.040 |
Why?
|
| DNA Primers | 1 | 1997 | 543 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 720 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 853 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 65 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2818 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1997 | 381 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 1621 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1565 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2020 | 3241 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1313 | 0.030 |
Why?
|
| Alleles | 1 | 1997 | 1128 | 0.030 |
Why?
|
| Benztropine | 1 | 2013 | 4 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1683 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 1208 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 2378 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 138 | 0.030 |
Why?
|
| RNA Probes | 1 | 1998 | 16 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2013 | 709 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1998 | 258 | 0.020 |
Why?
|
| Exons | 1 | 1998 | 450 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Rod Cell Outer Segment | 1 | 2005 | 2 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 25 | 0.020 |
Why?
|
| Saimiri | 1 | 2005 | 50 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2005 | 41 | 0.020 |
Why?
|
| Papio | 1 | 2005 | 82 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 229 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2005 | 128 | 0.020 |
Why?
|
| Immunochemistry | 1 | 2003 | 16 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 2003 | 108 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2003 | 72 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 129 | 0.010 |
Why?
|
| Response Elements | 1 | 2003 | 63 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 429 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 782 | 0.010 |
Why?
|
| Genes, Synthetic | 1 | 2001 | 7 | 0.010 |
Why?
|
| Lac Operon | 1 | 2001 | 46 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2001 | 44 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 88 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 536 | 0.010 |
Why?
|
| Cysteine Dioxygenase | 1 | 2001 | 1 | 0.010 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2001 | 6 | 0.010 |
Why?
|
| Oxygenases | 1 | 2001 | 13 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 393 | 0.010 |
Why?
|
| Methyltransferases | 1 | 2001 | 182 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 1294 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1540 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 3968 | 0.010 |
Why?
|